Search Results - "Apperley, JF"

Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma by Terpos, Evangelos, Rezvani, Katayoun, Basu, Supratik, Milne, Alison E., Rose, Peter E., Scott, Geoffrey L., Rahemtulla, Amin, Samson, Diana, Apperley, Jane F.

“…:  Autologous (ASCT) and allogeneic stem cell transplantations (alloBMT) are well‐established therapies for multiple myeloma. However, patients continue to…”
Get full text

Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey by Salooja, N, Szydlo, RM, Socie, G, Rio, B, Chatterjee, R, Ljungman, P, Lint, MT Van, Powles, R, Jackson, G, Hinterberger-Fischer, M, Kolb, HJ, Apperley, JF

“…Some patients treated by transplantation of haemopoietic stem cells (peripheral blood or bone marrow) become permanently infertile, but others retain or…”
Get full text

Anti-angiogenic effect of bortezomib in patients with multiple myeloma by Politou, Marianna, Naresh, Kikkeri, Terpos, Evangelos, Crawley, Danielle, Lampert, Irvin, Apperley, Jane F, Rahemtulla, Amin

Get more information

Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting by Lishner, Michael, Avivi, Irit, Apperley, Jane F, Dierickx, Daan, Evens, Andrew M, Fumagalli, Monica, Nulman, Irena, Oduncu, Fuat S, Peccatori, Fedro Alessandro, Robinson, Susan, Van Calsteren, Kristel, Vandenbroucke, Tineke, Van den Heuvel, Frank, Amant, Frederic

“…The incidence of hematologic malignancies during pregnancy is 0.02%. However, this figure is increasing, as women delay conception until a later age. Systemic…”
Get full text

Treatment and management of graft-versus-host disease: improving response and survival by Garnett, Catherine, Apperley, Jane F., Pavlů, Jiří

“…Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogenic haematopoietic stem-cell transplantation and thus the…”
Get full text

Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations by Robertson, H F, Buckton, M J, Apperley, J F

“…TKIs are paradigmatic in CML management and offer patients the prospect of a normal life expectancy. As a consequence, the focus of both the clinician and…”
Get more information

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning by Crawley, Charles, Iacobelli, Simona, Björkstrand, Bo, Apperley, Jane F., Niederwieser, Dietger, Gahrton, Gösta

“…Despite the widespread adoption of reduced-intensity conditioning (RIC) for myeloma, there are few data comparing outcomes with RIC with myeloablative…”
Get full text

Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index by Terpos, Evangelos, Szydlo, Richard, Apperley, Jane F., Hatjiharissi, Evdoxia, Politou, Marianna, Meletis, John, Viniou, Nora, Yataganas, Xenophon, Goldman, John M., Rahemtulla, Amin

“…Interaction between receptor activator of nuclear factor κB ligand (RANKL) and RANK/osteoprotegerin (OPG) plays a dominant role in osteoclast activation and…”
Get full text

A survey of the prophylaxis and treatment of acute GVHD in Europe : a report of the European Group for Blood and Marrow Transplantation (EBMT) by RUUTU, T, NIEDERWIESER, D, GRATWOHL, A, APPERLEY, J. F

“…A survey was carried out among EBMT (European Group for Blood and Marrow Transplantation) centres of the practical details of the prophylaxis and treatment of…”
Get full text

Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials by Stem Cell Trialists' Collaborative Group

“…Considerable uncertainty exists regarding relative effects of allogeneic peripheral blood stem cells transplantation (PBSCT) versus bone marrow transplantation…”
Get full text

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta by Apperley, Jane F, Gardembas, Martine, Melo, Junia V, Russell-Jones, Robin, Bain, Barbara J, Baxter, E. Joanna, Chase, Andrew, Chessells, Judith M, Colombat, Marie, Dearden, Claire E, Dimitrijevic, Sasa, Mahon, François-X, Marin, David, Nikolova, Zariana, Olavarria, Eduardo, Silberman, Sandra, Schultheis, Beate, Cross, Nicholas C.P, Goldman, John M

“…Imatinib mesylate blocks the activity of three protein tyrosine kinases: ABL, KIT, and platelet-derived growth factor receptor β (PDGFRB). These kinases have…”
Get full text

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT by Crawley, Charles, Lalancette, Marc, Szydlo, Richard, Gilleece, Maria, Peggs, Karl, Mackinnon, Stephen, Juliusson, Gunnar, Ahlberg, Lucia, Nagler, Arnon, Shimoni, Avichai, Sureda, Anna, Boiron, Jean-Michel, Einsele, Herman, Chopra, Rajesh, Carella, Angelo, Cavenagh, Jamie, Gratwohl, Alois, Garban, Frederic, Zander, Axel, Björkstrand, Bo, Niederwieser, Dietger, Gahrton, Gösta, Apperley, Jane F.

“…We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity conditioning (RIC) regimens from 33 centers within the…”
Get full text

Primary plasma cell leukemia and autologous stem cell transplantation by DRAKE, Mary B, IACOBELLI, Simona, VAN BIEZEN, Anja, MORRIS, Curly, APPERLEY, Jane F, NIEDERWIESER, Dietger, BJÖRKSTRAND, Bo, GAHRTON, Gösta

“…Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple…”
Get full text

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT by Crawley, Charles, Szydlo, Richard, Lalancette, Marc, Bacigalupo, Andrea, Lange, Andrzej, Brune, Mats, Juliusson, Gunnar, Nagler, Arnon, Gratwohl, Alois, Passweg, Jakob, Komarnicki, Mieczysław, Vitek, Antonin, Mayer, Jiri, Zander, Axel, Sierra, Jorge, Rambaldi, Alessandro, Ringden, Olle, Niederwieser, Dietger, Apperley, Jane F.

“…This study reports outcomes of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning (RIC) in 186 patients with chronic…”
Get full text

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML by Yong, Agnes S.M., Szydlo, Richard M., Goldman, John M., Apperley, Jane F., Melo, Junia V.

“…Although most patients with chronic myeloid leukemia (CML) have the same initial molecular abnormality, the BCR-ABL fusion gene, the duration of chronic phase…”
Get full text

Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma by Terpos, Evangelos, Politou, Marianna, Szydlo, Richard, Goldman, John M., Apperley, Jane F., Rahemtulla, Amin

“…The role of serum macrophage inflammatory protein‐1 alpha (MIP‐1α) in bone disease and survival was evaluated in 85 newly diagnosed multiple myeloma (MM)…”
Get full text

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib by KHORASHAD, J. S, ANAND, M, KAEDA, J, MARIN, D, SAUNDERS, S, AL-JABARY, T, IQBAL, A, MARGERISON, S, MELO, J. V, GOLDMAN, J. M, APPERLEY, J. F

“…The expansion of a leukemia clone bearing a Bcr-Abl kinase domain mutation is associated with acquired resistance to imatinib and may also predict disease…”
Get full text

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia by Schmitz, Norbert, Beksac, Meral, Hasenclever, Dirk, Bacigalupo, Andrea, Ruutu, Tapani, Nagler, Arnon, Gluckman, Eliane, Russell, Nigel, Apperley, Jane F., Gorin, Norbert C., Szer, Jeff, Bradstock, Ken, Buzyn, Agnes, Clark, Peter, Borkett, Keith, Gratwohl, Alois

“…Allogeneic mobilized peripheral blood progenitor cells instead of bone marrow are increasingly used to restore hematopoiesis after myeloablative therapy. Data…”
Get full text

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation by Cristina, Trento, Bernardo, Maria Ester, Nagler, Arnon, Kuci, Selim, Bornhäuser, Martin, Köhl, Ulrike, Strunk, Dirk, Gaipa, Giuseppe, Introna, Martino, Lazzari, Lorenza, Apperley, Jane F., Bukauskas, Adomas, Le Blanc, Katarina, Van Campenhout, Ann, Beguin, Yves, Kuball, Jurgen, van der Werf, Steffi Maria, Ruiz de Elvira, Carmen, Chabannon, Christian, Roelofs, Helene, Bonini, Chiara, Dazzi, Francesco

“…The immunosuppressive properties of mesenchymal stromal cells (MSC) have been widely exploited in the clinical setting to control severe graft-versus host…”
Get full text

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients by O'SHEA, D, GILES, C, KANFER, E, OLAVARRIA, E, APPERLEY, J. F, RAHEMTULLA, A, TERPOS, E, PERZ, J, POLITOU, M, SANA, V, NARESH, K, LAMPERT, I, SAMSON, D, NARAT, S

“…High-dose therapy with autologous stem cell therapy (ASCT) has become the treatment of choice for eligible patients with myeloma. We analysed retrospectively…”
Get full text